Capstone Holding
Holding Companies & Conglomerates · Arizona, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1275 W Washington St Ste 101, Tempe, Ari...Phone Number
(602) 286-5520Website
www.capstonethx.comRevenue
$46.1 MillionStock Symbol
CAPSIndustry
About Capstone Holding
Capstone Therapeutics was a biotechnology company committed to developing novel therapeutic peptides aimed at helping patients with under-served medical conditions. This Agreement results in the Company's exit from the pharmaceutical development business. In March 2020 the Company entered into a transaction, which was effective April 1, 2020, whereby it has obtained an interest in a materials distribution company (Totalstone, LLC) that distributes masonry stone products for residential and commercial construction in the Midwest and Northeast United States, under the trade names Instone and Northeast Masonry Distributors (NMD), which going forward will be the Company's primary business activity. Capstone's corporate headquarters are located in Alsip, Illinois.Explore more
SIC Code 67,671NAICS Code 55,551Ticker OTC: CAPSShow moreCapstone Holding Org Chart
Compare Similar Companies to Capstone Holding
Compare insights from companies similar to Capstone Holding, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$132.7M
51-200
Public
$547.1M
1994
JB
Jennifer BuellPresident and CEO of MiNK Therapeutics, Chairman, Executive Council At Agenus
Capstone Holding Tech Stack
A closer look at the technologies used by Capstone Holding
See more technologies
Top Holding Companies & Conglomerates Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Capstone Holding
Sign Up For FreeTo access detailed company insights
Capstone Therapeutics was a biotechnology company committed to developing novel therapeutic peptides aimed at helping patients with under-served medical conditions. This Agreement results in the Company's exit from the pharmaceutical development business. In March 2020 the Company entered into a transaction, which was effective April 1, 2020, where... Read More